Effectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease : a case report
- PMID: 32054604
- DOI: 10.1136/annrheumdis-2020-216983
Effectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease : a case report
Keywords: inflammation; juvenile idiopathic arthritis; pulmonary fibrosis.
Conflict of interest statement
Competing interests: None declared.
Comment in
-
Response to: 'Effectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease: case report' by Bader-Meunier et al.Ann Rheum Dis. 2022 Feb;81(2):e21. doi: 10.1136/annrheumdis-2020-217000. Epub 2020 Feb 13. Ann Rheum Dis. 2022. PMID: 32054603 No abstract available.
Comment on
-
Emergent high fatality lung disease in systemic juvenile arthritis.Ann Rheum Dis. 2019 Dec;78(12):1722-1731. doi: 10.1136/annrheumdis-2019-216040. Epub 2019 Sep 27. Ann Rheum Dis. 2019. PMID: 31562126 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical